Study: Lowering cholesterol during melanoma immunotherapy
Part of Cancer, Heart & circulation, Skin clinical trials.
This study tests whether giving aggressive cholesterol-lowering medication to people starting immunotherapy for melanoma can improve heart health. It may help reduce the risk of heart problems during cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 55 or older, or a woman aged 65 or older.
- You have been diagnosed with melanoma and are about to start immunotherapy (drugs like PD-1, PD-L1, CTLA-4, or LAG3 inhibitors).
- You have not had any prior major heart events (heart attack, stroke, or heart surgery).
- You can have a heart scan called CCTA, meaning you have no allergies to contrast dye, no serious kidney problems, and no uncontrolled irregular heartbeat.
- Your fasting LDL "bad" cholesterol is less than 190 mg/dL.
- Your initial heart scan shows some plaque but no severe blockages.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking a statin (a cholesterol-lowering medicine) during immunotherapy for melanoma can prevent heart problems. It may help protect your blood vessels while you receive cancer treatment.
This study looks at how common medicines might interact with immunotherapy (a treatment that helps your immune system fight cancer). Participation could help doctors learn how to better manage side effects and dosing for patients on these treatments.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This study tests whether adding a special diet (with prebiotic foods) to standard immunotherapy before surgery helps your body fight melanoma better. It may improve how well the treatment works and reduce side effects.
This trial tests whether adding anakinra and tocilizumab to the usual combination of nivolumab and ipilimumab can improve treatment for melanoma. It is for people aged 50 or older who are about to start this standard treatment.
This trial looks at whether adding a program of exercise and nutrition changes can improve quality of life and treatment outcomes for people with melanoma who are starting immunotherapy. If you qualify, you would take part in a structured plan to see if these lifestyle changes help.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.